Human complement receptors 1 and 2 are well described as important regulators of innate and adaptive immune responses, having pivotal roles in regulating complement activation (CR1) and B-cell maturation/survival. In contrast, the role of the murine homologs of CR1 and CR2 (mCR1/2) have been primarily defined as modulating activation of the adaptive immune system, with very little evidence available about the role of mCR1/2 in regulating the innate immune responses to pathogens. In this paper, we confirm that mCR1/2 plays an important role in regulating both the innate and adaptive immune responses noted after Adenovirus (Ad)-mediated gene transfer. Our results uncovered a novel role of mCR1/2 in downregulating several complement-dependent innate immune responses. We also unveiled the mechanism underlying the complement-dependent induction of neutralizing antibodies to Ad capsids as a CR1/2-dependent phenomenon that correlates with B-cell activation. These results confirm that Ad interactions with the complement system are pivotal in understanding how to maximize the safety or potency of Ad-mediated gene transfer for both gene therapy and vaccine applications.
Introduction
Adenovirus (Ad)-based vectors offer tremendous capabilities as potent vaccine platforms, primarily reflected by their superior ability to induce both humoral and cellular immune responses to desired antigens expressed by the vectors. It is widely believed that the known ability of Ad vectors to induce proinflammatory cytokine responses may contribute to Ad vector-mediated induction of potent immune responses. However, strainspecific neutralizing antibodies to Ads can hinder the ability to repeatedly administer the vector as a boosting immunogen, prompting multiple efforts to develop alternative serotype Ad vectors to overcome this problem. It is with these realities in mind that studies investigating the mechanisms underlying the induction of neutralizing antibodies to the well-characterized Ad5 vector platform are required. Importantly, the Ad5 serotype is the only Ad serotype utilized in all human gene transfer clinical trials (4367 as per September 2008, comprising 24.9% of all gene therapy trials to date); please see http://www.wiley.co.uk/wileychi/genmed/ clinical/.
Our previous studies have confirmed that the induction of neutralizing antibodies to Ads is dependent on the presence of a functional complement system in the host. 1 Although we have discovered that the protein C3 is essential in this response, the mechanisms underlying C3-dependent induction of neutralizing antibody by Ad vectors is currently unknown. Our previous results confirm that lack of Ad interactions with the C3 protein results in a diminished induction of proinflammatory cytokines and acute phase responses early after Ad administration, suggesting that a lack of this initial response may contribute to diminished induction of neutralizing antibody responses. This hypothesis is supported by recent studies in interferon (IFN) receptor knockout (KO) mice that also showed diminished induction of neutralizing antibody titers after Ad treatments. 2 We have utilized Ad-treated CR1/2-KO mice in this study to test this hypothesis.
It is known that complement system activation acts to optimize induction of pathogen-specific antibody responses. [3] [4] [5] After opsonization by activated C3, pathogens are bound to B cells and dendritic cells via binding of pathogen-bound C3 to the complement receptors (CRs). The human CR1 and CR2 (hCR1 and hCR2) receptors have well-known roles in modulating both innate and adaptive immune responses. hCR1 is a potent inhibitor of complement activation, having both decay-accelerating and cofactor activities. Furthermore, hCR1 has a critical role in the clearance of immune complexes and B-cell maturation, as thoroughly reviewed elsewhere. 6, 7 hCR2 expression is restricted to the surface of B cells, follicular dendritic cells and thymocytes. When hCR2 binds C3d-opsonized pathogens and becomes associated with CD19, it lowers the threshold for B-cell activation by up to 1000-fold. 8 HCR1 and hCR2 also play a role in T-cell biology, for example, cross-linking of hCR1 inhibits T-cell proliferation and interleukin (IL)-12 production. 9 Murine complement receptors (mCRs) 1 and 2 (CD35/ CD21) are products of alternative splicing from the same gene. mCR1 contains 21 complement control protein repeats (CCPRs), whereas the smaller mCR2 contains only 15 C-terminal CCPRs of mCR1. 10 mCR1/2 is known to be expressed on B cells and dendritic cells. 10 Therefore, the expression pattern of mCR1/2 resembles that of hCR2, but not of hCR1. Similar to their human homologs, the functions of mCR1/2 related to generation of maximal humoral responses have been well described. [11] [12] [13] [14] [15] Interestingly, mCR1/2 functionality prevents excessive myocardial tissue damage after coxsackievirus B3 infection, 16 as well as lethal Streptococcus pneumoniae infection, a role potentially indirectly reflective of the complement inhibitory activities of the CRs. 17 Although the role of murine CR1/2 protein has been extensively studied in regards to adaptive immune responses, its function in inhibiting/regulating murine complement has not been demonstrated, possibly because in most mouse models, the Crry protein was suggested to play the predominant role in controlling complement activation. We feel that the role of murine CR1/2 protein in innate immune responses (including the ones which are known to be complement dependent) may be more important than previously considered, as suggested by our present studies of Ad-mediated gene transfer into mCR1/2-KO mice. Our results in murine models revealed dual roles for mCR1/2; roles that include downregulation of multiple aspects of the Ad-induced innate immune responses, and also playing the major role in the complement-dependent induction of neutralizing antibody responses to Ads.
Results
Murine complement receptor 1/2 regulates Ad-mediated cytokine and chemokine release in C57BL/6 mice To study the role of mCR1/2 protein in Ad-induced innate and adaptive immune responses, we utilized mCR1/2-KO mice. These mice have been previously demonstrated to completely lack expression of CR1/2 on B cells. 17 It is also known that CR1/2 activities also impact on levels of activated C3, by virtue of CR1/2's decay-accelerating properties. Utilizing western blotting with C3-specific antibodies, we confirmed that mockinjected CR1/2-KO mice have normal overall levels of C3 no different than wild-type (WT) mice, and equivalent amounts of C3 cleavage products were present in the plasma of virus-injected WT and CR1/2-KO mice, as investigated both at 10 min and 6 h post-injection ( Supplementary Figure 1) . These results suggest that CR1/2-KO mice do not have significant alterations in the ability of C3 to initially interact with Ads, an interaction that we have previously confirmed mediates many Ad-induced innate and adaptive immune responses. 1, [18] [19] [20] [21] Inflammatory cytokines and chemokines are rapidly released after systemic Ad injection. We have identified seven cytokines and chemokines (KC or CXCL1, MCP-1, MIP-1b, G-CSF, RANTES, IL-6, IL-12p40) that become significantly elevated within hours of systemic administration of Ad vectors, some of which are elevated in a C3-dependent fashion. 18, 21 We investigated the role that mCR1/2 has in the induction of these cytokines by administering Ads into WT and mCR1/2 KO mice. Plasma samples, collected at 1 and 6 h after intravenous Ad administration confirmed that KC and monocyte chemoattractant protein-1 (MCP)-1 chemokines are rapidly released in response to Ad injections and reach maximum levels by 1 hpi. Ad-injected mCR1/2-KO mice had identical levels of activation of these two chemokines at 1 hpi ( Figure 1 ), suggesting that Ad induction of these very early mediators of the inflammatory responses is not dependent on mCR1/2 functionality. Interestingly, Ad-injected mCR1/2-KO mice exhibited significantly higher plasma levels of granulocyte colony-stimulating factor (G-CSF), MCP-1 and RANTES at 6 h after systemic Ad injection, as compared to identically treated WT mice ( Figure 1 ). This result identifies the role of functional mCR1/2 protein as a complement regulator that suppresses complement activation, resulting in diminished production of several cytokines released after Ad administration in mice. This result may reflect a complement decay-accelerating property of mCR1/2 thought to be present in the extracellular portion of the protein, based on analogy to the hCR1/2 homologs.
Portions of the acute and chronic cellular responses to Ad vectors are Complement Receptor 1/2 dependent
Activation of vascular endothelium is a critical step during initiation of inflammatory immune responses, because many inflammatory cells (that is, platelets, neutrophils, macrophages, mast cells) utilize activated endothelial cells (EC) as a means to localize to damaged sites. This response is mediated by activated EC overexpression of E-selectin, ICAM-1 and/or VCAM-1 adhesion molecules on their surface, molecules that facilitate the migration of inflammatory cell types into damaged organs. [22] [23] [24] Soluble forms of these cell adhesion molecules are also produced by activated ECs. 25 Interestingly, although the levels of sE-selectin in Adtreated WT mice were increased threefold, sE-selectin levels in Ad-treated mCR1/2-KO mice were at least sevenfold higher, as compared to mock-injected mCR1/2-KO mice, these levels were also significantly higher than levels noted in Ad-treated WT mice ( Figure 2 ). Induction of both sVCAM-1 and sICAM-1 was also slightly more robust in Ad-treated mCR1/2-KO mice as compared to Ad-injected WT mice, although these levels did not reach a significant difference (data not shown). We have also tested the level of ICAM-1, VCAM-1 and Eselectin mRNA transcripts in murine liver at 6 hpi after systemic Ad injection and found significantly increased levels of all 3 transcripts in mCR1/2-KO mice ( Table 1) . These results confirm that lack of mCR1/2 functionality results in a more robust induction of cellular adhesion 1, 21, 26 However, at 24 h after systemic Ad injection, mCR1/2-KO mice exhibited levels of thrombocytopenia no different than that noted in Ad-injected WT mice (data not shown). Adinjected mCR1/2-KO mice trended toward elevated levels of neutrophils and reduced levels of lymphocytes at 24 hpi, though the changes did not reach statistical significance when compared to identically treated WT mice. There was also no difference in levels of Kupffer cell necrosis in virus-treated WT and mCR1/2-KO mice, suggesting that mCR1/2 is not involved in Kupffer cell necrosis, an event that occurs within hours of Ad injection (data not shown). 27 Systemically administered Ad vectors induce significant leukocyte infiltration into the liver. 28, 29 The infiltration becomes apparent at 3 dpi, continuously increases with the generation of an adaptive immune response to the virus and/or antigen it expresses, and reaches maximal levels by 21-56 dpi. 29, 30 We have quantified monocellular (leukocyte) infiltration into the livers of Ad-treated WT and mCR1/2-KO mice at 28 dpi. Both WT and mCR1/2-KO Ad-injected mice exhibited significant infiltration of inflammatory cells into their livers, as compared to mock-injected animals. Despite the previously noted enhanced proinflammatory cytokine responses, as well as enhanced activation of ECs in Adinjected mCR1/2-KO mice, Ad-injected mCR1/2-KO mice had significantly reduced periportal inflammation as well as total levels of hepatic inflammation relative to Ad-injected WT mice ( Supplementary Figures 2a and b ). Portal and lobular inflammation were somewhat reduced in virus-treated mCR1/2-KO mice as compared to identically treated WT mice, although these differences did not reach statistical significance. These results suggest that maximal induction of cellular inflammation after Ad vector administration is directly dependent on mCR1/2, despite enhanced activation of the innate immune system in the same animals earlier.
Murine complement receptor 1/2 downregulates Ad induction of proinflammatory genes in livers of Ad-treated C57BL/6 mice
We have previously confirmed that systemic administrations of Ad vectors results in a rapid and profound transcriptome response in the murine liver, responses that are mediated by Ad interactions with the murine complement system. 20, 21, 31 Based, in part, on those studies, we analyzed expression levels of several liver gene transcripts, including those participating in innate immune responses, that is, pattern recognition receptors (Toll-like receptors (TLRs), NODs), TLR signaling pathways (MyD88, TRIF, TRAF6, TRAF2bp, TBK1), markers of EC activation (ICAM1, VCAM1, E-selectin), IFNresponsive genes (ADAR, OAS1a, IRF7, IRF8), all listed in Table 1 . Note that none of the genes tested showed any differences in basal transcription levels between mock-injected WT and mCR1/2-KO mice liver-derived 
The numbers represent mean±s.d. Statistical analysis was completed using one-way ANOVA with a Student-Newman-Keuls post hoc test, Po0.05 was deemed a statistically significant difference. Note, when significant Po0.001 was observed in majority of cases. N ¼ 4 for mock-injected groups, N ¼ 6 for virus injected groups was used. Significant differences compared to C57BL/6_WT_Mock are highlighted in grey color. Significant inductions of transcriptional activation in CR1/2-KO_Ad5-LacZ group compared to WT_Ad5-LacZ group are indicated in table with black frame and boldface font. Note that no significant differences were detected between mock-injected WT and CR1/2-KO mice.
Murine CR1/2 regulates Adenovirus-induced immune responses SS Seregin et al transcripts. However, the levels of 13 liver transcripts, although significantly induced in Ad-injected WT mice at 6 hpi, were induced to statistically greater levels in Ad-treated mCR1/2-KO mice. These Ad-induced, but mCR1/ 2-suppressed, genes included ADAR, ICAM1,  VCAM1, E-selectin, MyD88, TBK1, TLR2, TLR3, JAK3,  SOCS1 . Importantly, five gene transcripts, that were not induced in Ad-injected WT mice (as compared to mockinjected animals) also revealed significant inductions in mCR1/2-KO Ad-treated mice ( Table 1 ). These observations allowed us to conclude that mCR1/2 plays a significant role in downregulating Ad induction of proinflammatory gene expression. Importantly, the Ad induction of most of these genes has also been previously shown by us to be a complement protein C3-dependent event, suggesting that mCR1/2 downregulates Ad activation of proinflammatory genes by suppressing and/or regulating the overall levels of Ad-induced, C3dependent activation of the complement system. 1, 21 Ad-mediated transduction in vivo is not dependent on murine complement receptor 1/2, but the levels of Ad-derived transgene expression are complement and mCR1/2 dependent
We next confirmed that Ad-mediated liver transduction of Ad genomes was not diminished at any time point tested during our studies (Figure 3a ), in part, confirming our previously published results that complement does not significantly mediate Ad transduction efficacy in vivo. 1 Ad-derived transgene expression in livers of treated mice was then tested by two independent techniques: qualitatively by staining liver sections with 5-bromo-4chloro-3-indolyl-b-D-galactopyranoside (X-Gal; Figure 3b ) and by quantitative measurement of b-galactosidase (b-Gal) activity at 6 hpi, 24 hpi and 28 dpi ( Figure 3c ). We found a significant reduction of b-Gal activity in mCR1/2-KO mice as compared to WT mice both at 24 hpi and 28 dpi, but not at 6 hpi (Figures 3b and c). Adinjected C3-KO mice also exhibited significantly reduced b-Gal activity both at 6 hpi and 24 hpi, a trend that we and others have noted previously. 1, 21, 32 Our observations confirm that lack of mCR1/2 functionality does not dramatically alter the ability of Ads to transduce their genomes into the murine liver per se, but rather results in a more rapid shutdown of cytomegalovirus (CMV) enhancer dependent transgene expression from Ad vectors, a complex finding elaborated on further in the discussion section of this paper.
Murine complement receptor 1/2 is required for generation of Ad vector-specific, but not transgenespecific, adaptive immune responses
Ad-specific adaptive immune responses can be primed by the robustness of innate immune responses. 2, 9, 33 Our results confirm that mCR1/2 protein suppresses or downregulates many Ad-induced innate immune responses, therefore, we wished to determine whether enhanced induction of Ad-induced innate immune responses (due to lack of mCR1/2 function) altered subsequent adaptive immune responses to the vector capsid, and/or the transgene product the Ad vector expresses. Importantly, we first confirmed that baseline immunoglobulin G (IgG) levels in mock-injected WT and mCR1/2-KO mice were identical (data not shown), confirming previously published observations. 9, 11, 12, 33 However, our results demonstrated that Ad-injected mCR1/2-KO mice had diminished Ad capsid-specific primary humoral responses (as compared to identically treated WT mice) both at 14 and 28 dpi ( Figure 4 ). IgA, total IgG, IgG1, IgG2a, IgG3 subtypes of Ad capsidspecific antibodies tested in Ad-treated mCR1/2-KO mice were significantly reduced at least at one of the two time points tested as compared to Ad-injected WT mice, moreover, all were diminished both at 14 and 28 dpi in mCR1/2-KO mice (Figure 4 ). Additionally, Ad-injected mCR1/2-KO mice did not generate significant titers of Ad capsid-neutralizing antibodies, as determined both at 14 and 28 dpi ( Figure 5 ). These observations strongly parallel our previously published data noting that Adinjected C3-KO mice also exhibit a diminished capacity to generate anti-Ad capsid-specific humoral responses, as well as neutralizing antibody responses. 1 As B cells are known to express high levels of mCR1/2, and depend on mCR1/2 for induction of antigen-specific B-cell activation, we quantified B-cell activation 48 h after systemic Ad injection into WT, C3-KO and mCR1/2-KO mice. We confirmed that the number of activated B cells (that is, CD19 + /CD69 + splenocytes) was significantly increased in WT mice injected with Ad vectors as compared to uninfected WT mice ( Figure 6 ). Interestingly, the levels of B-cell activation were significantly and identically reduced in both Ad-treated C3 and mCR1/2-KO mice, again as compared to identically injected WT mice, suggesting that the C3-dependent portion of induction of neutralizing antibody responses to Ad capsids may be entirely mediated by interactions mediated by the CR1/2 protein ( Figure 6 ). This result positively correlates with our findings that functional mCR1/2 protein is required to generate Ad capsidspecific humoral immune responses (Figures 4 and 5 ), a response that is at least, in part, a complementdependent event. 1 The overall results suggest that induction of neutralizing antibodies to Ads is dependent on C3-opsonized Ads interacting with mCR1/2 present on B cells, resulting in their activation.
Finally, we have previously published that the lack of complement protein C3 did not reduce the induction of transgene-specific humoral responses in Ad-injected mice. 1 Interestingly, mCR1/2-KO mice injected with Ad5-LacZ generated levels of transgene-specific (b-Gal) antibodies that paralleled those noted in identically treated WT mice ( Supplementary Figure 3) . Only b-Galspecific IgA, total IgG and IgG2a reached significant differences, and this occurred at only one of the two time points tested. These results suggest that Ad-expressed, transgene-specific adaptive immune responses are not dependent on mCR1/2.
Discussion
Despite the fact that the role of mCR1/2 in modulating adaptive immune responses has been extensively studied, 11, 12, 34, 35 very little information is available regarding the role of mCR1/2 in regulating aspects of the innate immune system, including complement mediated responses. In this study we have investigated the role of mCR1/2 protein in regulating Ad vector-Murine CR1/2 regulates Adenovirus-induced immune responses SS Seregin et al induced innate immune responses and also assessed what impact these roles have on downstream adaptive immune responses to the Ad vector and/or to the transgene the vector expresses.
We have previously described the pivotal role the complement system has in generating robust innate immune responses after Ad treatment, including systemic proinflammatory cytokines/chemokine release, EC activation, acute thrombocytopenia and liver transcriptome dysregulation. 1, 21 In this study we have shown that many of these complement-dependent responses are modulated (suppressed) by mCR1/2.
To highlight how mCR1/2 specifically downregulates Ad-dependent induction of proinflammatory cytokines and chemokine responses we have combined data obtained in this study with our previously published (Figure 7 ). 1 Note, that MCP-1, IL-12p40, G-CSF and RANTES are all induced in a complement-dependent manner (evident by the lack of induction of these cytokines/chemokines in C3-KO mice). Moreover, mCR1/2 protein downregulates the induction of these very chemokines (MCP-1, G-CSF and RANTES) as compared to Ad-treated WT mice. These overall results reveal that mCR1/2 plays a very important role in suppressing overall innate immune responses induced by complement system activation by Ad vectors. This suppressive activity of mCR1/2 is not without precedent, as it has been shown that mCR1/2 is required to prevent excessive tissue damage after coxsackievirus B3 infection. 16 In addition, lack of mCR1/2 functionality results in an enhanced susceptibility (that is, lethality) after S. pneumoniae infection. 17 Note, that none of these studies focused on the role of mCR1/2 in innate immunity, as most studies regarding modulation of the murine complement system and the innate immune responses have focused on the CR-1 related protein (Crry). 36, 37 Those studies indirectly suggest that murine Crry has taken over some hCR1 functions, that is, those roles relative to mCR1/2 acting as a murine complement inhibitor. 10, 38 We feel that our studies confirm a significant role for mCR1/2 in suppressing the activation of the murine complement system, and innate immune responses derived from that activation. Why the mouse has what appears to be a redundant complement inhibiting activities (present in Crry and mCR1/2) will require future experimentation but this redundancy may have contributed as to why humans lack Crry.
As both MCP-1 and G-CSF are known to activate macrophages, 39 and both RANTES and G-CSF activate neutrophils, 39 it might be hypothesized that lack of mCR1/2 might result in an enhanced infiltration of these inflammatory cells to the sites normally transduced by Ad vectors (that is, liver). However, our results were not able to detect substantial increases in acute, Adinduced cellular responses in the livers of Ad-injected mCR1/2-KO mice, suggesting that recruitment of these cells requires additional factors.
Preexisting immunity to Ads remains a main hindrance for numerous applications utilizing Ad-based vectors as a vaccine platform. In light of this fact, it is of critical importance to study the mechanisms underlying generation of Ad capsid-specific antibody responses. Increased innate immune responses are generally thought to positively correlate with enhanced inductions of humoral, and/or cellular adaptive immune responses. 2, 9, 33 The complement system is well known to significantly impact on the generation of humoral responses to pathogens by facilitating interactions between the innate and adaptive response systems. [6] [7] [8] Our previous results demonstrated that Ad vector administrations into C3-KO mice resulted in diminished cytokine and chemokine responses, and a diminished induction of neutralizing antibodies to Ad. 1, 21 However, despite enhanced induction of proinflammatory cytokines and chemokines rapidly after Ad vector administrations into CR1/2-KO mice, we still found a dramatically reduced induction of neutralizing antibodies to the Ad vector capsid. These results positively correlated with a lack of activation of B cells in Ad-injected C3-KO and mCR1/2-KO mice. The combined observations suggest that lack of induction of proinflammatory cytokine responses early after Ad administrations into C3-KO mice is not the reason for lack of neutralizing antibody induction in the Ad-treated C3-KO mice. 1 Rather, C3-opsonized Ad interactions with mCR1/2 on murine B cells is primarily responsible for induction of neutralizing antibodies to the Ad vector capsid. This insight suggests that further investigation of this interaction may promote strategies to proactively modulate the induction of neutralizing antibodies to Ad vectors.
Zaiss et al. 40 detected evidence of Ad induction of neutralizing antibodies in an alternative CR1/2-KO mouse model. That strain of CR1/2-KO mouse has a different portion of the murine Cr2 gene disrupted, relative to the CR1/2-KO mouse strain utilized in our Additional technical caveats including the use of a significantly different assay system may also explain the differing results. Our multiple findings demonstrating a lack of significant induction of Ad capsidneutralizing antibodies in both Ad-treated C3-KO and CR1/2-KO mice, as well as our finding that Ad induction of B-cell activation is also significantly decreased in these same strains of mice strongly support our conclusion that CR1/2 does play an important role in the induction of neutralizing antibodies to Ad vectors. Although Zaiss et al. did not report on whether or not induction of neutralizing antibodies to Ads occurred in Ad-treated C3-KO mice, Zaiss et al. did find that mCR1/2 functions were also necessary for induction of neutralizing antibodies to AAV-based vectors. The latter results, combined with ours, suggest that mCR1/2 may be playing a role in the induction of neutralizing antibodies to several commonly utilized gene transfer vectors. Interestingly, activation of type I interferons (IFNa/b), have also been shown to play a role in the induction of Ad-specific humoral adaptive immune responses, whether these responses are due to, or a result of Ad interactions with the complement system, and CR1/2 specifically will require future investigations. 2 In a similar vain, we found that an increased induction of Ad-induced innate immune responses in mCR1/2-KO mice did not correlate with increased induction of adaptive immune responses to a foreign antigen expressed by an Ad vector. The reasons for this observation are not due to a diminished ability of the Ad vector to transduce cells in mCR1/2-KO mice, but rather appear to correlate with reduced transgene expression levels in Ad vector-treated mCR1/2-KO mice both at 24 hpi and 28 dpi. Possibly, the globally altered cytokine and chemokine responses noted after Ad administration into CR1/2-KO mice indirectly decreases activity of the CMV-derived enhancer/promoter element utilized to drive expression of the expression foreign transgene encoded by the vector, a possibility that will require experiments beyond the scope of this paper. We previously reported that transgene-specific adaptive immune responses were higher in Ad-treated C3-KO mice as compared to identically Ad-treated WT mice. 1 At the least, those results suggested that lack of complement activation does not significantly interfere with generation of transgene-specific antibody responses by Ad vectors. Thus, targeted blockade of complement system activation that prevents C3-opsonized Ads from interacting with the CR1/2 receptor may minimize induction of antibody responses to the Ad capsid whereas simultaneously preserving or enhancing the ability of the Ad to induce beneficial immune responses to Ad-expressed foreign antigens.
Our results may also suggest a possible mechanism as to how noncovalent modifications of Ad vectors (such as Ad PEGylation) may allow for avoidance of induction of neutralizing antibodies, by indirectly minimizing their induction of the complement system. [41] [42] [43] We also suggest that these findings may allow for improved use of Ad vectors as a vaccine platform, though such studies are beyond the scope of this manuscript. However, several previous studies indirectly confirmed roles for the complement system in generation of robust Adinduced adaptive immune responses, in particular in Ad vaccine settings utilizing C4-binding protein or C3d as novel adjuvants. [44] [45] [46] [47] [48] In conclusion, we have confirmed the role of mCR1/2 in regulating and/or suppressing several Ad-induced innate immune responses, and also confirmed that mCR1/2 modulates the induction of adaptive immune responses to the Ad vector. Although the former observation now confirms that in mice, mCR1/2 can play an important role in downregulating complementdependent innate immune responses in a manner that is independent of Crry, the latter observations suggests that Ad vector interactions with mCR1/2 also figure prominently in induction of neutralizing antibodies to Ads.
Materials and methods

Adenovirus vector production and characterization
A first-generation, human Ad type 5-derived replication deficient vector (deleted for the E1 genes) encoding b-Gal (LacZ) as a transgene (Ad5-LacZ) was used in this study. Virus construction, propagation and purification were performed as previously described. 49, 50 Briefly, a number of serial passages on HEK293 cells allowed high titer purification of Ad5-LacZ by sequential, cesium chloride density gradient centrifugations. Purified virus was dialyzed against 10 mM Tris (pH 8.0) and stored in 1% sucrose, 1 Â phosphate-buffered saline (PBS) at À80 1C until use. Viral particle (vp) and transducing unit titers (bfu ml À1 ) were determined as previously described, and were 2.6 Â 10 12 vp ml À1 and 1.8 Â 10 11 bfu ml À1 , respectively. 21, 51 The vp to bfu ratio was B14:1. Virus was found to be RCA free both by RCA PCR (E1 region amplification) and direct sequencing methods as previously described. 20 Ad vector has also been tested for the presence of bacterial endotoxin as previously described, 28 and was found to contain o0.01 EU per injection dose.
Animal procedures
Adult C57BL/6 WT and B6.129S4-C3tmlCrr (C3-KO) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). mCR1/2-KO mice in C57BL/6 background were a kind gift from Dr Tedder, Duke University Medical Center. 17, 52 The Ad vector were injected intravenously (via the retro-orbital sinus) into 8-to 10-week old male C57BL/6 mice after performing proper anesthesia with isofluorane. A total of 0.75 Â 10 11 vp in 200 ml of PBS was injected per mouse. Four groups of mice were analyzed in this study: C57BL/6 WT and CR1/2-KO mice, mock injected with PBS and C57BL/ 6_WT or CR1/2-KO mice injected with Ad5-LacZ. For some of the control experiments C3-KO mice were utilized (N ¼ 4 for all C3-KO groups). Mice were killed at different times after mock or virus treatment: 6 hpi (N ¼ 6 for virus-injected groups, N ¼ 4 for mock-injected groups), 24 hpi (N ¼ 4 for all groups), 28 dpi (N ¼ 5 for all groups). Plasma and tissue samples were collected and Figure 7 Murine complement receptor 1/2 (mCR1/2) protein plays a significant role in downregulation of Adenovirus (Ad)mediated complement-dependent proinflammatory cytokines production. This graph summarizes the data obtained in this study (Figure 1 ) and our previously published data on Ad-mediated cytokine release in C3-KO mice. 1 Plasma levels (at 6 hpi) of proinflammatory cytokines and chemokines in Ad-injected CR1/2-KO and C3-KO mice are normalized to the levels of WT_Ad5-LacZ. Levels higher than the ones observed in wild-type (WT) mice have positive fold induction (CR1/2-KO mice), whereas reduced levels compared to the levels of WT mice (C3-KO) have negative fold induction. Shaded area represents the levels of cytokines release in Ad-injected WT mice. * , **Represent a statistically significant differences between Ad-injected WT and complement (CR1/2 or C3) knockout (KO) mice, Po0.05, Po0.001, respectively. Note, that monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-12p40, granulocyte colony-stimulating factor (G-CSF) and RANTES are all induced in a complementdependent manner (evident by the lack of induction of these cytokines/chemokines in C3-KO mice). Moreover, mCR1/2 protein downregulates the induction of these very molecules (MCP-1, G-CSF and RANTES).
Murine CR1/2 regulates Adenovirus-induced immune responses SS Seregin et al processed at the indicated time points in accordance with Michigan State University Institutional Animal Care and Use Committee. All procedures with recombinant Ads were performed under BSL-2, and all vector-treated animals were maintained in ABSL-2 conditions. All animal procedures were reviewed and approved by the Michigan State University ORCBS and IACUC. Care for mice was provided in accordance with PHS and AAALAC standards.
Cytokine/chemokine/endothelial cells activation markers release measurement
To determine if mCR1/2 protein has any effect on Admediated release of cytokines/chemokines, Ad-induced systemic release of proinflammatory cytokines/chemokines in murine plasma was measured in all groups of mice utilizing a multiplex bead array system. Plasma samples were collected at 1 and 6 hpi using heparinized capillary tubes and EDTA-coated microvettes (Sarstedt, Nü mbrecht, Germany) and centrifuged at 3400 r.p.m. for 10 min to retrieve plasma samples. Samples were assayed for seven independent cytokines/chemokines, which we have previously shown to be rapidly induced by systemically injected Ad vectors (MCP-1, KC, MIP-1b, IL-6, IL-12p40, G-SCF, RANTES). 1, [19] [20] [21] All procedures were performed exactly as previously described according to manufacturer's instructions (BioRad, Hercules, CA, USA) via Luminex 100 technology (Luminex, Austin, TX, USA). 20 The measurement of soluble ICAM-1, VCAM-1 and E-selectin molecules (EC activation markers) in murine plasma (collected at 6 hpi) was performed utilizing mouse cardiovascular disease panel LINCOplex kit (Millipore, Billerica, MA, USA) as per manufacturer's instructions. 
Complete blood count analysis and cell type differentiation
Platelet enumeration
To access Ad vector-induced thrombocytopenia in C57BL/6 WT and CR1/2-KO mice, platelets were measured 24 hpi after systemic Ad injection by using Unopette (Fisher Scientific) system as previously described 20, 21 as per manufacturer's recommendations. Platelets were subsequently manually counted using Neubauer hemocytometer. Note, that platelets were counted by two independent methods.
b-Galactosidase enzyme activity and in situ X-Gal staining
Ad-mediated expression of the transgene LacZ was measured both qualitatively and quantitatively as follows. Liver sections from animals scarified at 6 hpi, 24 hpi and 28 dpi were embedded in optimal cutting temperature (OCT) compound, frozen and stored at À80 1C until use. Frozen samples were sectioned (7 mm sections) on a Leica cryostat and were fixed and in situ stained for LacZ expression using X-Gal (1 mg ml À1 ) as previously described. 30 For quantitative assay, enzyme b-Gal activity was measured in snap frozen liver samples. Liver samples (o0.1 g) were homogenized and total protein concentration was determined by bicinchoninic acid assay (Pierce, Rockford, IL, USA). b-Gal activity was quantified by use of a b-Gal activity detection kit (Stratagene, La Jolla, CA, USA) according to manufacturers instructions and as previously described. 29 Data were reported as units of b-Gal activity per mg of total protein.
qRT-PCR Analysis
To determine relative levels of a specific, liver-derived RNA transcript, liver tissues were snap frozen in liquid nitrogen and RNA was harvested from E100 mg of frozen tissue using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) per the manufacturer's protocol. Following RNA isolation, reverse transcription was performed on 180 ng of total RNA using SuperScript II (Invitrogen) reverse transcriptase (RT) and random hexamers (Applied Biosystems, Foster City, CA, USA) per manufacturer's protocol. RT reactions were diluted to a total volume of 60 ml, and 2 ml was used as the template in the subsequent PCR reactions. Primers were designed using Primer Bank web-based software (http://pga.mgh. harvard.edu/primerbank/). Some primers used for amplification have been previously described. 18, 21 Complete list of primers utilized in this study is available in Supplementary Table 1 . Quantitative PCR (qPCR) was carried out on an ABI 7900HT Fast Real-Time PCR System using SYBR Green PCR Mastermix (Applied Biosystems) in a 15 ml reaction. All PCRs were subjected to the following procedure: 95.0 1C for 10 min followed by 40 cycles of 95.0 1C for 15 s followed by 60.0 1C for 1 min. The comparative C t method was used to determine relative gene expression using GAPDH to standardize expression levels across all samples. Relative expression changes were calculated based on comparing experimental levels of a respective liver transcript to those quantified in liver samples derived from mockinjected animals.
Antibody titering assay
ELISA-based titering experiments were essentially completed as previously described. 53 
B-cell activation assay/flow cytometry
Early activation of B cells was studied by flow cytometry-based methods. 0.75 Â 10 11 vp per mouse of Ad5-lacZ was injected intravenously into WT, CR1/2-KO or C3-KO mice. Forty-eight hours after Ad injection splenocytes were harvested, and CD19+ cells examined for expression of CD69 activation marker. Briefly, after harvesting splenocytes at 48 hpi from individual mice, RBCs were lysed by using ACK lysis buffer (Invitrogen). Splenocytes were subsequently washed two times with RPMI medium 1640 (Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine, 1% PSF (penicillin, streptomycin, fungizone), resuspended and counted. Two million cells were first washed two times with cold fluorescenceactivated cell sorting (FACS) buffer and then incubated for 15 min with purified rat anti-mouse CD16/CD32 Fc block (BD Biosciences, San Diego, CA, USA). For surface staining, cells were washed one time with FACS buffer and incubated on ice for 30 min with the following antibodies, APC-CD3 (8 mg ml À1 ), PerCpCy5.5-CD19 (8 mg ml À1 ) and FITC-CD69 (10 mg ml À1 ; all BD Biosciences). Samples were analyzed on BD LSR II instrument and analyzed using FlowJo software (Tree Star, San Carlos, CA, USA).
Kupffer cell staining
Liver blocks, preserved in OCT compound at À80 1C, were sliced into 7 mM sections using a cryostat, placed on glass slides and frozen at À80 1C for future use. Slides were thawed, fixed in 100% ethanol for 15 min and washed in KPBS containing 0.2% gelatin and 0.05% tween-20. Sections were permeabilized in 0.1% triton-X100 and blocked with KPBS containing 0.1% gelatin, 1% tween-20 and 5% BSA for 60 min at room temperature.
To prevent nonspecific binding of the secondary antibody, 5% rabbit serum in wash buffer was added and incubated at room temperature for 30 min. Rat antimouse F4/80 antibody (Invitrogen) diluted to 5.2 mg ml À1 in wash buffer containing 2% rabbit serum was added to the sections and incubated overnight at 4 1C. Sections were washed and incubated at room temperature for 45 min with rabbit anti-rat Alexafluor-488 (Invitrogen) secondary antibody diluted 1:25 000 in wash buffer containing 2% rabbit serum. Sections were then washed, stained with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI; Invitrogen) for 5 min at room temperature and mounted using VECTASHIELD (Vector Laboratories, Burlingame, CA, USA). Images were obtained using a Leica DMLB microscope, and captured using SPOT software v.3.5.9. Both DAPI and F4/80 stained images were transferred to Adobe Photoshop and converted to grayscale. The background threshold was set based on mock-injected livers, and pixels were quantified. F4/80 fluorescence values were normalized to DAPI fluorescence values to control for cell number differences. Values are reported as percent relative to number of Kupffer cells identically enumerated in liver tissues derived from mock-injected control mice.
Hematoxylin and eosin staining
To study the role of mCR1/2 in Ad vector-mediated hepatic inflammation at 28 dpi, Hematoxylin and Eosin (H&E) staining of mouse liver samples was performed as previously described. 29 Briefly, tissues were fixed in 10% neutral formalin for 12 h, washed in 70% ethanol, embedded in paraffin and 6-mm sections were stained with H&E. We have adapted a previously developed semiquantitative scoring system, which allows the level of hepatic pathology between different liver sections to be quantified and statistically compared. 29 For every mouse, 10 liver sections obtained at different portions of the liver (0-1000 mm from liver surface) were analyzed and given a numerical score (0-3) for three different categories of liver pathology:
(1) Portal inflammation 0-no portal inflammation 1-low-moderate number of inflammatory cells (macrophages, lymphocytes) evident in o1/3 of portal tracts 2-moderate number of inflammatory cells in 1/3 to 2/3 of portal tracts 3-high number of inflammatory cells in over 2/3 of portal tracts
(2) Periportal inflammation 0-no inflammation 1-low-moderate number of inflammatory cells infiltration evident around o1/3 of portal tracts 2-moderate number of inflammatory cells infiltrated through 1/3 to 2/3 of portal tracts, in majority of which they take less that 50% of circumference. Minimum hepatocellular necrosis observed 3-moderate-high number of inflammatory cells infiltrated through over 2/3 of portal tracts or infiltrated through over 1/3 of tracts but occupy over 50% of circumference in at least 50% of them. Two independent researchers have scored all the slides in a blind manner and the averages of their scores were taken. The sum of scores (10 slides) for each mouse was taken and individual category scores were averaged for each group. Total inflammation index was computed by averaging the sum of all three individual category scores for each mouse.
Ad genome copy number per liver cell
To determine the number of Ad genome copies per liver cell at different time points posttransduction liver tissues (o0.1 g) were snap frozen in liquid nitrogen, crushed to a fine powder using a mortar and pestle and total DNA was extracted from as previously described. 54 Ad genome copy numbers were assessed using Real-Time PCR-based quantification. PCR reactions were performed on an ABI 7900HT Fast Real-Time PCR System using the SYBR Green PCR Mastermix as described for qRT-PCR technique. Primers generated against the Ad5 Hexon gene have been previously described. 18 As an internal control for ensuring adequate DNA amplification, liver DNA was quantified using primers spanning the GAPDH gene. Standard curves were run in duplicate and consisted of 6 half-log dilutions using total genomic DNA, or DNA extracted from the purified Ad5-LacZ virus. These standard curves were used to determine the number of viral genomes present per liver cell. Melting curve analysis confirmed the quality and specificity of the PCR (data not shown).
Western blotting
To determine if mCR1/2 protein has any effect on levels of major complement protein C3 (or its cleavage products) in murine plasma, we have performed western blotting utilizing murine C3-specific polyclonal antibody, which also recognizes C3 cleavage products (Abcam, Cambridge, MA, USA). Assay was performed as previously described. 37 Briefly, 5 ml of murine plasma, collected at 10 min post-injection or 6 hpi from all four groups of mice, utilized in this study was loaded on 7.5% SDS-polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membranes and probed with C3 antibody. Subsequently, the blot was probed with secondary fluorescent antibodies, scanned and quantified utilizing Licor's Odyssey scanner. 55 
Statistical analysis
For every experiment, pilot trials were performed with thrree mice per group. This allowed us to determine effect size and sample variance so that Power Analysis could be performed to correctly determine the number of subjects per group required to achieve a statistical power40.8 at the 95% confidence level. Statistically significant differences in toxicities associated with innate immune response (that is, platelet counts, gene induction and others) were determined using one-way analysis of variance (ANOVA) with a Student-Newman-Keuls post hoc test (P-valueo0.05). Furthermore, a two-way ANOVA with a Bonferroni post hoc test was used to analyze the levels of cytokines at 1 and 6 hpi to determine significant differences (Po0.05) between groups. For antibody titering assays, liver H&E stains, b-Gal activity and Ad genomes in mouse liver, a twotailed Student's t-test was used to compare two groups of virus-injected animals (Po0.05). All graphs in this paper are presented as mean of the average±s.d. GraphPad Prism software was utilized for statistical analysis.
